Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstructive Coronary Artery Disease (IMPROVE-Ischemia)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 23, 2021

Primary Completion Date

September 21, 2023

Study Completion Date

September 21, 2023

Conditions

IschemiaCoronary Artery Disease

Interventions

DRUG

IMB-1018972

Modified release (MR) oral tablet

DRUG

Placebo

Matching oral tablet

Trial Locations (3)

Imbria Investigational Site, Aarhus

Imbria Investigational Site, Turku

Imbria Investigational Site, Uppsala